Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Synchrony Financial enters its July 20 Q2 earnings print with the Street in an unusually constructive mood — two firms raised price targets on the same morning this week, even as the stock dipped nearly 2% on the day.
The analyst move is the standout this week. TD Cowen and UBS both lifted targets on July 7, with TD Cowen nudging its Buy-rated target to $90 and UBS, maintaining a Neutral stance, jumping from $77 to $84. That puts the consensus mean around $89.78 — roughly 19% above the current price of $75.52. The broader pattern since April tells a similar story: Barclays raised to $93, Baird to $86, and Truist to $82 following last quarter's print, more than offsetting a downgrade from BTIG to Neutral in April. The direction of travel on the Street is clearly upward, even if a handful of firms stay on the sidelines. The bull case rests on credit trends running better than feared, a cheap valuation — the P/E has re-rated up about half a point over the past month but still sits near 7.7x — and an active buyback program. Bears counter that the non-co-branded card segment remains under pressure from APR-driven competitor share gains, and that the stock at 1.5x book already prices in some of the recovery.
Short positioning tells a relaxed story ahead of the print. Short interest has drifted lower all month — down roughly 1.6% on the week and about 12% from the mid-June peak of around 22.8 million shares — landing at 5.6% of the free float. That's meaningful but not elevated for a consumer lender. The borrow market is about as loose as it gets: availability is running at more than 1,600% of short interest, meaning for every share currently borrowed, there are roughly sixteen more available in the pool. Cost to borrow has eased to 0.44% — down 22% on the week — after briefly touching 0.57% at month-end. The ORTEX short score of 46.2 sits near the middle of its range and has barely moved in two weeks. None of this signals a short squeeze setup or an aggressive bear case being built in the lending market.
Options positioning is similarly neutral. The put/call ratio of 1.04 is almost exactly in line with its 20-day average of 1.04, with a z-score effectively at zero. That's a sharp contrast to late June, when the PCR was running above 1.37 — the elevated put demand seen then has since unwound entirely. With earnings less than two weeks away, the absence of incremental hedging activity is notable. The 52-week PCR range runs from 0.03 to 1.95, so the current reading is neither crowded to the downside nor particularly bullish.
Insider activity has been one-directional but is unlikely to concern investors. Every transaction in the past 90 days has been a sale, totalling roughly $46 million in net value. The CFO sold in early March, the CEO sold in early March, and the Chief Legal Officer sold in mid-May. Trade significance scores were low (2/10) across the board, and the sales follow the stock's recovery from the April lows — likely planned disposals rather than a bearish signal. Institutional holders show no drama: BlackRock added modestly in Q2, First Trust added over 1.8 million shares, and the largest holder Capital Research trimmed a negligible 35,000 shares. The ownership base looks stable.
Among close peers, SYF is holding ground. BFH fell nearly 6% on the week and ATLC dropped 6.6%, while ALLY lost about 4%. COF was roughly flat. SYF's 0.7% weekly decline compares favorably against that group, consistent with its more moderate short positioning and improving credit narrative. The nearest comparable earnings reaction to watch: SYF jumped 4.6% the day after its last print in late June, though the five-day return faded to just 2.3%.
With the Q2 report due July 20, the tension worth watching is whether actual net charge-off data and updated 2026 guidance corroborates the lower loss estimates that drove the recent analyst target lifts — or whether the non-co-branded segment headwinds show up more visibly in the numbers.
See the live data behind this article on ORTEX.
Open SYF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
